The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
Hepatitis B infects over 40 million people in India
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Subscribe To Our Newsletter & Stay Updated
